Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. more
Time Frame | RLMD | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.38% | -2.06% | -0.55% |
1-Month Return | -88.3% | -1.92% | 2.72% |
3-Month Return | -89.88% | -10.4% | 7.66% |
6-Month Return | -88.34% | -4.6% | 10.15% |
1-Year Return | -85.92% | 4.06% | 27.53% |
3-Year Return | -98.28% | 1.94% | 32.31% |
5-Year Return | -99.18% | 36.48% | 89.2% |
10-Year Return | -99.41% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 4.87K | 3.75K | 1.26K | - | - | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":77.04,"profit":true},{"date":"2021-12-31","value":25.83,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | (4.87K) | (3.75K) | (1.26K) | - | - | [{"date":"2019-12-31","value":-487000,"profit":false},{"date":"2020-12-31","value":-375200,"profit":false},{"date":"2021-12-31","value":-125800,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 12.73M | 60.84M | 125.70M | 161.25M | 103.70M | [{"date":"2019-12-31","value":7.89,"profit":true},{"date":"2020-12-31","value":37.73,"profit":true},{"date":"2021-12-31","value":77.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":64.31,"profit":true}] |
Operating Income | (12.73M) | (60.84M) | (125.70M) | (161.25M) | (103.70M) | [{"date":"2019-12-31","value":-1272792000,"profit":false},{"date":"2020-12-31","value":-6083867300,"profit":false},{"date":"2021-12-31","value":-12570349200,"profit":false},{"date":"2022-12-31","value":-16124907600,"profit":false},{"date":"2023-12-31","value":-10370200000,"profit":false}] |
Total Non-Operating Income/Expense | - | 2.78M | 1.15M | 6.86M | 10.06M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":27.64,"profit":true},{"date":"2021-12-31","value":11.44,"profit":true},{"date":"2022-12-31","value":68.22,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (17.32M) | (59.46M) | (125.75M) | (157.04M) | (98.79M) | [{"date":"2019-12-31","value":-1731806000,"profit":false},{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704382300,"profit":false},{"date":"2023-12-31","value":-9879174600,"profit":false}] |
Income Taxes | 4.59M | (1.38M) | 48.32K | (2.66M) | (103.70K) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-30.11,"profit":false},{"date":"2021-12-31","value":1.05,"profit":true},{"date":"2022-12-31","value":-57.94,"profit":false},{"date":"2023-12-31","value":-2.26,"profit":false}] |
Income After Taxes | - | (58.07M) | (125.80M) | (154.38M) | (98.69M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5807411500,"profit":false},{"date":"2021-12-31","value":-12580012600,"profit":false},{"date":"2022-12-31","value":-15438439900,"profit":false},{"date":"2023-12-31","value":-9868804400,"profit":false}] |
Income From Continuous Operations | - | (59.46M) | (125.75M) | (157.04M) | (98.79M) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704382300,"profit":false},{"date":"2023-12-31","value":-9879174600,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (17.32M) | (59.46M) | (125.75M) | (157.04M) | (98.79M) | [{"date":"2019-12-31","value":-1731806000,"profit":false},{"date":"2020-12-31","value":-5945639400,"profit":false},{"date":"2021-12-31","value":-12575180900,"profit":false},{"date":"2022-12-31","value":-15704382300,"profit":false},{"date":"2023-12-31","value":-9879174600,"profit":false}] |
EPS (Diluted) | (1.35) | (3.81) | (7.14) | (5.45) | (3.28) | [{"date":"2019-12-31","value":-135,"profit":false},{"date":"2020-12-31","value":-381,"profit":false},{"date":"2021-12-31","value":-714,"profit":false},{"date":"2022-12-31","value":-545,"profit":false},{"date":"2023-12-31","value":-328,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RLMD | |
---|---|
Cash Ratio | 6.69 |
Current Ratio | 6.89 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RLMD | |
---|---|
ROA (LTM) | -59.13% |
ROE (LTM) | -100.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RLMD | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.15 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.85 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RLMD | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 0.23 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.54 |
Relmada Therapeutics Inc (RLMD) share price today is $0.3533
Yes, Indians can buy shares of Relmada Therapeutics Inc (RLMD) on Vested. To buy Relmada Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RLMD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Relmada Therapeutics Inc (RLMD) via the Vested app. You can start investing in Relmada Therapeutics Inc (RLMD) with a minimum investment of $1.
You can invest in shares of Relmada Therapeutics Inc (RLMD) via Vested in three simple steps:
The 52-week high price of Relmada Therapeutics Inc (RLMD) is $7.22. The 52-week low price of Relmada Therapeutics Inc (RLMD) is $0.35.
The price-to-earnings (P/E) ratio of Relmada Therapeutics Inc (RLMD) is
The price-to-book (P/B) ratio of Relmada Therapeutics Inc (RLMD) is 0.23
The dividend yield of Relmada Therapeutics Inc (RLMD) is 0.00%
The market capitalization of Relmada Therapeutics Inc (RLMD) is $10.91M
The stock symbol (or ticker) of Relmada Therapeutics Inc is RLMD